Spots Global Cancer Trial Database for secondary hyperparathyroidism
Every month we try and update this database with for secondary hyperparathyroidism cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) | NCT03299244 | Secondary Hyper... Chronic Kidney ... | Etelcalcetide Cinacalcet | 18 Years - | Amgen | |
| Intravenous Paricalcitol in Chronic Hemodialysis Patients | NCT03023748 | Endstage Renal ... Secondary Hyper... | Intravenous Par... | 18 Years - 75 Years | The University of Hong Kong | |
| Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D | NCT00977080 | Chronic Kidney ... Secondary Hyper... Hemodialysis | Paricalcitol Cinacalcet | 18 Years - | Abbott | |
| SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis | NCT03626948 | Secondary Hyper... | SK-1403 | 20 Years - | Sanwa Kagaku Kenkyusho Co., Ltd. | |
| Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism | NCT01341782 | Secondary Hyper... Hemodialysis | paricalcitol maxacalcitol paricalcitol pl... maxacalcitol pl... | 20 Years - | AbbVie | |
| Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis | NCT00446329 | Secondary Hyper... | cinacalcet | 18 Years - | Papageorgiou General Hospital | |
| ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism | NCT00135304 | Secondary Hyper... | Sensipar® Vitamin D | 18 Years - | Amgen | |
| Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis | NCT00446329 | Secondary Hyper... | cinacalcet | 18 Years - | Papageorgiou General Hospital | |
| A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis | NCT02133404 | Secondary Hyper... | ASP7991 Cinacalcet Placebo | 20 Years - 79 Years | Astellas Pharma Inc | |
| Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients | NCT01447368 | Kidney Failure Secondary Hyper... Vascular Diseas... | Cinacalcet Surgical total ... | 18 Years - 75 Years | The University of Hong Kong | |
| Phase 3 Study of KHK7580 | NCT02549404 | Secondary Hyper... | KHK7580 | 20 Years - | Kyowa Kirin Co., Ltd. | |
| Changes in Cardiac Functions in Patients Treated With Parathyroidectomy for Secondary Hyperparathyroidism | NCT06187480 | Secondary Hyper... Myocardial Dysf... | total parathyro... | 18 Years - 80 Years | Mersin University | |
| Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism | NCT01081665 | Chronic Kidney ... Secondary Hyper... | 18 Years - | Abbott | ||
| Single-Cell Sequence Technology Used to Reveal Heterogeneity of Secondary Hyperparathyroidism | NCT06130683 | Secondary Hyper... | Single-cell seq... | 18 Years - 80 Years | China-Japan Friendship Hospital | |
| Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis | NCT00446329 | Secondary Hyper... | cinacalcet | 18 Years - | Papageorgiou General Hospital | |
| LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients | NCT01167309 | Secondary Hyper... | LEO 27847 | 18 Years - 75 Years | LEO Pharma | |
| Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) | NCT01219855 | Chronic Kidney ... Secondary Hyper... Vitamin D Insuf... | Cohort 1 CTAP10... Cohort 1 CTAP10... Cohort 1 Matchi... Cohort 2 CTAP10... Cohort 2 Matchi... | 18 Years - 85 Years | OPKO Health, Inc. | |
| Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients | NCT00958451 | Secondary Hyper... Chronic Kidney ... | Paricalcitol Ergocalciferol | 18 Years - | Salem Veterans Affairs Medical Center | |
| A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | NCT03969329 | Secondary Hyper... | Etelcalcetide | 2 Years - 17 Years | Amgen | |
| A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism | NCT01653379 | Secondary Hyper... | DP001 | 18 Years - | Deltanoid Pharmaceuticals | |
| Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism | NCT00754442 | Secondary Hyper... | Teriparatide | 40 Years - 59 Years | University of Maryland, Baltimore | |
| Phase 3 Study of SK-1403 | NCT03801980 | Secondary Hyper... | SK-1403 Placebo | 20 Years - | Sanwa Kagaku Kenkyusho Co., Ltd. | |
| Treatment of Secondary Hyperparathyroidism in the Uremic Patient | NCT00469599 | Secondary Hyper... Chronic Kidney ... Vitamin D Defic... | paricalcitol alfacalcidol | 18 Years - | Zealand University Hospital | |
| A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism | NCT04994080 | Secondary Hyper... | Paricalcitol Placebo | 18 Years - | Chengdu Suncadia Medicine Co., Ltd. | |
| Phase 2 Study of KHK7580 | NCT02216656 | Secondary Hyper... | Placebo KHK7580 low dos... KHK7580 middle ... KHK7580 high do... KRN1493 | 20 Years - 74 Years | Kyowa Kirin Co., Ltd. | |
| A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis | NCT03633708 | Secondary Hyper... Chronic Kidney ... | Etelcalcetide | 0 Years - 18 Years | Amgen | |
| Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis | NCT02143271 | Secondary Hyper... | KHK7580 | 20 Years - 74 Years | Kyowa Kirin Co., Ltd. | |
| A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism | NCT01149291 | Secondary Hyper... End Stage Renal... | 18 Years - | AbbVie | ||
| A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis | NCT02133404 | Secondary Hyper... | ASP7991 Cinacalcet Placebo | 20 Years - 79 Years | Astellas Pharma Inc | |
| Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia | NCT03822507 | Secondary Hyper... | KHK7580 Cinacalcet Hydr... | 18 Years - | Kyowa Kirin Co., Ltd. | |
| Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism | NCT03226171 | Secondary Hyper... | Dose-adjusted S... | 20 Years - 79 Years | Sanwa Kagaku Kenkyusho Co., Ltd. | |
| Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) | NCT00823303 | Secondary Hyper... Chronic Kidney ... | Paricalcitol Calcitriol | 18 Years - | Washington University School of Medicine | |
| A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis | NCT02133404 | Secondary Hyper... | ASP7991 Cinacalcet Placebo | 20 Years - 79 Years | Astellas Pharma Inc | |
| A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis | NCT03633708 | Secondary Hyper... Chronic Kidney ... | Etelcalcetide | 0 Years - 18 Years | Amgen | |
| ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism | NCT00135304 | Secondary Hyper... | Sensipar® Vitamin D | 18 Years - | Amgen | |
| Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism | NCT00307840 | Secondary Hyper... | paricalcitol | 18 Years - | Papageorgiou General Hospital | |
| Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis | NCT01265992 | Secondary Hyper... Chronic Kidney ... | 18 Years - | AbbVie | ||
| Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD) | NCT01479088 | Secondary Hyper... | Cinacalcet HCl | 2 Years - 18 Years | Istituto Giannina Gaslini | |
| Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism | NCT01254565 | Secondary Hyper... | Etelcalcetide Placebo | 18 Years - | KAI Pharmaceuticals | |
| Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis | NCT01265992 | Secondary Hyper... Chronic Kidney ... | 18 Years - | AbbVie | ||
| Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) | NCT03299244 | Secondary Hyper... Chronic Kidney ... | Etelcalcetide Cinacalcet | 18 Years - | Amgen | |
| Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose | NCT00891813 | Secondary Hyper... Renal Insuffici... Parathyroid Hor... Hemodialysis Hypercalcemia | Zemplar (parica... | 18 Years - | Abbott | |
| Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose | NCT00891813 | Secondary Hyper... Renal Insuffici... Parathyroid Hor... Hemodialysis Hypercalcemia | Zemplar (parica... | 18 Years - | Abbott | |
| Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism | NCT00123461 | Secondary Hyper... Renal Failure Chronic Renal I... | Hectorol (doxer... | 18 Years - | Sanofi | |
| A Study of SHR6508 in Secondary Hyperparathyroidism | NCT05663411 | Secondary Hyper... | SHR6508 SHR6508 Cinacalcet | 18 Years - | Shanghai Hengrui Pharmaceutical Co., Ltd. | |
| A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients | NCT00037635 | Secondary Hyper... End Stage Renal... | AMG 073 Placebo | 18 Years - | Amgen | |
| Treatment of Secondary Hyperparathyroidism in the Uremic Patient | NCT00469599 | Secondary Hyper... Chronic Kidney ... Vitamin D Defic... | paricalcitol alfacalcidol | 18 Years - | Zealand University Hospital | |
| Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism | NCT01576146 | Secondary Hyper... | Etelcalcetide | 18 Years - | KAI Pharmaceuticals | |
| Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT) | NCT01224782 | Chronic Kidney ... Secondary Hyper... | 18 Years - | AbbVie | ||
| Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) | NCT01219855 | Chronic Kidney ... Secondary Hyper... Vitamin D Insuf... | Cohort 1 CTAP10... Cohort 1 CTAP10... Cohort 1 Matchi... Cohort 2 CTAP10... Cohort 2 Matchi... | 18 Years - 85 Years | OPKO Health, Inc. | |
| Morbidity Related to Secondary Hyperparathyroidism After Renal Transplantation | NCT01741064 | Secondary Hyper... Disorder Relate... | 18 Years - 85 Years | Skane University Hospital | ||
| Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT) | NCT00792857 | Chronic Kidney ... Secondary Hyper... Chronic Renal I... Chronic Renal F... | CTAP201 Injecti... Doxercalciferol | 18 Years - 80 Years | OPKO Health, Inc. | |
| Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D | NCT00977080 | Chronic Kidney ... Secondary Hyper... Hemodialysis | Paricalcitol Cinacalcet | 18 Years - | Abbott | |
| Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism | NCT05543928 | Chronic Kidney ... Chronic Kidney ... Vitamin d Defic... Secondary Hyper... | CTAP101 Placebo | 8 Years - 17 Years | OPKO Health, Inc. | |
| Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism | NCT00990704 | Secondary Hyper... Hemodialysis | paricalcitol maxacalcitol | 20 Years - | Abbott | |
| Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism | NCT01134562 | Hyperparathyroi... | Placebo Etelcalcetide | 18 Years - | KAI Pharmaceuticals | |
| Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects | NCT00664430 | Secondary Hyper... Dialysis | Calcitriol Paricalcitol | 18 Years - | Abbott | |
| Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet | NCT01896232 | Secondary Hyper... Chronic Kidney ... | Etelcalcetide Cinacalcet Oral Placebo Intravenous Pla... | 18 Years - 85 Years | Amgen | |
| A Trial of SHR6508 in Secondary Hyperparathyroidism | NCT05221008 | Secondary Hyper... | SHR6508；Placebo SHR6508；Placebo SHR6508；Placebo SHR6508；Placebo | 18 Years - 70 Years | Shanghai Hengrui Pharmaceutical Co., Ltd. | |
| Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism | NCT00573573 | Hyperparathyroi... | Far Infrared Ra... | - | GAAD Medical Research Institute Inc. | |
| Phase 3 Study of KHK7580 | NCT02549404 | Secondary Hyper... | KHK7580 | 20 Years - | Kyowa Kirin Co., Ltd. | |
| Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients | NCT01447368 | Kidney Failure Secondary Hyper... Vascular Diseas... | Cinacalcet Surgical total ... | 18 Years - 75 Years | The University of Hong Kong | |
| Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level | NCT01101113 | Secondary Hyper... | cinacalcet control | 18 Years - 70 Years | Seoul National University Hospital | |
| A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | NCT03969329 | Secondary Hyper... | Etelcalcetide | 2 Years - 17 Years | Amgen | |
| Changes in Cardiac Functions in Patients Treated With Parathyroidectomy for Secondary Hyperparathyroidism | NCT06187480 | Secondary Hyper... Myocardial Dysf... | total parathyro... | 18 Years - 80 Years | Mersin University | |
| Phase 3 Study of KHK7580 | NCT02549404 | Secondary Hyper... | KHK7580 | 20 Years - | Kyowa Kirin Co., Ltd. | |
| Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism | NCT00307840 | Secondary Hyper... | paricalcitol | 18 Years - | Papageorgiou General Hospital | |
| Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism | NCT00990704 | Secondary Hyper... Hemodialysis | paricalcitol maxacalcitol | 20 Years - | Abbott | |
| Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease | NCT01290029 | Chronic Kidney ... Hyperparathyroi... Secondary Hyper... | Cinacalcet | 28 Days - 2190 Days | Amgen | |
| Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism | NCT01576146 | Secondary Hyper... | Etelcalcetide | 18 Years - | KAI Pharmaceuticals | |
| Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients | NCT00415584 | Secondary Hyper... Hypercalcemia | Cinacalcet HCl | 18 Years - | Montefiore Medical Center | |
| A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | NCT03969329 | Secondary Hyper... | Etelcalcetide | 2 Years - 17 Years | Amgen | |
| A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis | NCT02133404 | Secondary Hyper... | ASP7991 Cinacalcet Placebo | 20 Years - 79 Years | Astellas Pharma Inc | |
| Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism | NCT01115543 | Secondary Hyper... End Stage Renal... | alfacalcidol an... | 18 Years - | Mahidol University | |
| The Efficacy and Safety of Microwave Ablation for Mild-to-moderate Secondary Hyperparathyroidism Patients Undergoing Hemodialysis | NCT02332135 | Secondary Hyper... Maintenance Hem... | microwave ablat... active vitamin ... | 18 Years - 75 Years | Beijing Friendship Hospital | |
| Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism | NCT01134562 | Hyperparathyroi... | Placebo Etelcalcetide | 18 Years - | KAI Pharmaceuticals | |
| The Trial of SHR6508 in Secondary Hyperparathyroidism | NCT06434961 | Secondary Hyper... | SHR6508 plus or... Cinacalcet plus... | 18 Years - | Shanghai Hengrui Pharmaceutical Co., Ltd. | |
| Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2 | NCT05836220 | Secondary Hyper... End Stage Kidne... | PLS240 Placebo Open-Label Exte... | 18 Years - 80 Years | Pathalys Pharma | |
| Quality of Life Change in Patients Undergoing Parathyroidectomy With End-stage Renal Failure | NCT06378931 | Secondary Hyper... End Stage Renal... | Quality of life... | 18 Years - | West China Hospital | |
| A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis | NCT00042653 | Secondary Hyper... End Stage Renal... | Placebo AMG 073 | 18 Years - | Amgen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
